2025 Highlights
Montefiore Einstein Neurology
World-renowned Neurologists.
Elite Biomedical Scientists.
Life-changing Results.
The Saul R. Korey Department of Neurology created a visionary model of neurological care that enabled us to envision neurological diseases as lifespan disorders, forever changing the lens through which neurological diseases are understood.
Childhood and early onset disorders necessitate different treatment modalities as the brain changes during adult life and aging. As medical breakthroughs have increased the median survival, our institution offers a destination site reflecting the aspiration that these patients can lead increasingly productive and fulfilling lives as they age. Research carried out in departmental laboratories has led to the paradigm-shifting discovery that aging likely starts at conception, and that the forerunners of late-onset dementias had their origin at the early stages of life, and account for the fact that these disorders in fact are systemic disorders that need to be treated in an interdisciplinary way. These revolutionary discoveries have profound implications for the early treatment of these currently untreatable conditions using a range of stem cell, epigenetic reprogramming and dynamic tissue remodeling strategies, thereby offering hope for the development of true disease-modifying treatments and even disease cures.
DATA & STATISTICS
2025 by the numbers
29,617
outpatient
32,583
inpatient
6,493
admissions
12,841
procedures
HIGHLIGHTS
Reimagining the Frontiers of Neurology Innovations by Igniting a Revolution in Understanding Disease Causality and Therapeutic Breakthroughs
CLINICAL TRIALS
Transforming the landscape of clinical care
At the Saul R. Korey Department of Neurology, we are committed to finding new and innovative options to prevent, diagnose, treat and cure neurologic diseases.
We are spearheading numerous clinical trials to advance treatments and receive notable NIH-funded grants, including our elite NINDS/NIH StrokeNet neurovascular clinical trials consortium grant.
We employ major clinical trials infrastructure from additional consortia as well as disease foundations and biotech and biopharma initiatives like this one for the study of a wide range of neurological diseases including age-associated dementia, Alzheimer’s disease, epilepsy, Multiple Sclerosis, and Huntington’s disease, as well as research that examines novel ways to restore brain function and studies that target the effects of COVID-19 on the brain in those with mild or asymptomatic infection, long COVID, as well as a new COVID neuro-critical illness we have identified that mediates dynamic brain-body communication and promotes accelerated aging that can be examined using newly defined molecular aging clocks and can be manipulated therapeutically.
A Phase 2/3 Multicenter, Randomization, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy
A Phase 2/3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BHV-7000 as Adjunctive Therapy in Subjects With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures, With
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients With Generalized Myasthenia Gravis
CAPTIVA: Comparison of Anti-coaA Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice (EVOLVE)gulation and Anti-platelet Therapies for Intracranial Vascular Atherostenosis
Seizure Forecasting Using Multimodal Data: The FORETELL Study
Seizure Predication Study
Team News
Updates and additions to our world-renowned faculty
Cast your vote
Polls on Doximity close soon. We hope you’ll consider nominating Montefiore Einstein Saul R. Korey Department of Neurology for the U.S. News & World Report Best Hospitals survey.
Contact Us
Mark F. Mehler MD, Chair, Neurology
mark.mehler@einsteinmed.edu







































